# Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

> **NCT07049159** · PHASE2 · RECRUITING · sponsor: **Eveliqure Biotechnologies GmbH** · enrollment: 72 (estimated)

## Conditions studied

- Shigella

## Interventions

- **BIOLOGICAL:** ShigETEC vaccine
- **OTHER:** Placebo
- **BIOLOGICAL:** Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU

## Key facts

- **NCT ID:** NCT07049159
- **Lead sponsor:** Eveliqure Biotechnologies GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2027-05-23
- **Final completion:** 2027-05-23
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07049159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07049159, "Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07049159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*